- The endocannabinoid system (ECS) was discovered in the early 1990s by Raphael Mechoulam and colleagues while researching how THC affects the brain.
- THC binds to CB1 receptors in the brain and CB2 receptors in immune tissue, mimicking the body’s own endocannabinoid anandamide.
- CBD does not bind directly to CB1 or CB2 receptors; it works by inhibiting FAAH (the enzyme that breaks down anandamide) and modulating serotonin and TRPV1 receptors.
- Inhaled cannabis reaches the brain in 30–60 seconds via the bloodstream; edibles take 30–90 minutes and produce a stronger metabolite (11-OH-THC) in the liver.
- The entourage effect describes synergy between cannabinoids and terpenes—the full plant often produces different effects than isolated compounds.
- Individual response to cannabis is shaped by genetics, CB1 receptor density, body composition, tolerance, and experience level.
The Endocannabinoid System (ECS)
The endocannabinoid system is one of the most important and least understood regulatory systems in the human body. It was discovered in the early 1990s when Israeli chemist Raphael Mechoulam and his team were studying how THC produces its effects. To understand why a plant compound could affect the brain so profoundly, they searched for a receptor it was binding to—and found CB1, the most abundant G protein-coupled receptor in the central nervous system.
The ECS consists of three core components: endocannabinoids (lipid-based signaling molecules your body synthesizes on demand), cannabinoid receptors (CB1 and CB2), and metabolic enzymes that synthesize and break down endocannabinoids. Unlike most neurotransmitter systems, endocannabinoids travel backward across synapses—from the receiving neuron back to the transmitting one—acting as a feedback brake on neural activity.
The two primary endocannabinoids are anandamide (N-arachidonoylethanolamide, or AEA) and 2-arachidonoylglycerol (2-AG). Anandamide—named after the Sanskrit word for bliss—is often called the body’s natural THC. It plays roles in mood regulation, memory consolidation, pain modulation, and appetite. The enzyme FAAH (fatty acid amide hydrolase) rapidly degrades anandamide, keeping its activity short-lived. CBD partially inhibits FAAH, which is one reason it elevates anandamide levels and produces anxiolytic effects.
The ECS does not exist purely to respond to cannabis. It evolved over hundreds of millions of years and is found in all vertebrate animals. Its primary function is homeostasis—maintaining physiological balance in systems including sleep, appetite, pain, immune function, reproductive health, and stress response. Cannabis works because its compounds happen to be structurally similar enough to endocannabinoids to activate the same receptors.
CB1 and CB2 Receptors: Where They Are and What They Do
CB1 receptors are the primary target of THC’s psychoactive effects. They are distributed throughout the central nervous system but concentrated in specific brain regions that map directly onto cannabis’s well-known effects. High CB1 density in the prefrontal cortex is responsible for altered decision-making and perception. CB1 activity in the hippocampus disrupts short-term memory formation. CB1 activation in the basal ganglia affects motor coordination. In the limbic system, CB1 modulates emotion and mood—explaining both the euphoria and the anxiety that can occur with high doses of THC.
CB2 receptors are found primarily in immune tissues—the spleen, tonsils, thymus, and on circulating immune cells. They play an important role in modulating inflammation and immune response. Unlike CB1, CB2 activation does not produce psychoactive effects, which has made CB2 an attractive target for pharmaceutical research into anti-inflammatory therapies. Some CB2 receptors are also present in the brain, particularly in microglial cells, and may play a neuroprotective role.
A third proposed receptor, GPR55 (sometimes called the CB3 receptor), may also respond to cannabinoids. Research into GPR55 and other orphan receptors suggests the endocannabinoid system is more complex than the original CB1/CB2 model, with additional targets including TRPV1, PPARs, and 5-HT3A.
What Happens When You Consume Cannabis
The route of administration dramatically affects how quickly cannabis works and how strong the effects are. The two primary pathways are inhalation and oral consumption, and they produce distinctly different pharmacokinetic profiles.
Inhalation: Smoking and Vaping
When cannabis is smoked or vaped, THC is absorbed through the alveoli in the lungs directly into the bloodstream. Because the blood-brain barrier is thin and highly vascularized, THC reaches the brain within 30–60 seconds. Peak blood THC concentrations occur within 3–10 minutes of inhalation. Effects begin almost immediately, peak within 30 minutes, and typically last 1.5–3 hours. Bioavailability via inhalation ranges from roughly 25–50% depending on inhalation technique and frequency.
Oral Consumption: Edibles and Capsules
Edibles follow a completely different metabolic pathway. THC is absorbed through the gastrointestinal tract, enters the portal vein, and passes through the liver before reaching systemic circulation. The liver converts THC into 11-hydroxy-THC (11-OH-THC), a metabolite that is more lipophilic and crosses the blood-brain barrier more efficiently than THC itself—producing effects that feel significantly more potent. Onset is delayed 30–90 minutes (sometimes longer), effects peak at 2–4 hours, and duration can extend to 6–8 hours. First-pass metabolism makes bioavailability highly variable (4–20%), which is why edible dosing is difficult to predict.
| Method | Onset | Peak | Duration | Bioavailability |
|---|---|---|---|---|
| Smoked | 30–90 sec | 15–30 min | 1.5–3 hrs | 25–50% |
| Vaped | 30–90 sec | 10–20 min | 1.5–2.5 hrs | 50–80% |
| Edibles | 30–90 min | 2–4 hrs | 4–8 hrs | 4–20% |
| Sublingual (tincture) | 15–45 min | 1–2 hrs | 2–4 hrs | 15–35% |
THC in the Brain: Region by Region
Once THC reaches the brain via the bloodstream, it disperses rapidly due to its lipophilic (fat-soluble) nature. It accumulates preferentially in regions with the highest CB1 receptor density, and the effects of cannabis map almost perfectly onto where those receptors live.
Prefrontal cortex: Governs executive function, decision-making, and abstract thinking. CB1 activation here produces altered time perception and associative ideation—but can also manifest as impaired judgment at high doses.
Hippocampus: The brain’s primary memory consolidation center. THC’s disruption here explains the short-term memory impairment during intoxication. This effect is transient and resolves as THC clears.
Nucleus accumbens and VTA: The reward pathway. THC indirectly triggers dopamine release along this pathway, creating euphoria and reinforcing repeat use. Cannabis activates this pathway less powerfully than stimulants or opioids.
Basal ganglia and cerebellum: Coordinate movement and motor learning. CB1 activation here explains why cannabis affects coordination and reaction time—effects with practical implications for driving.
Amygdala: Processes threat detection and emotional memory. High-dose THC can over-activate the amygdala, triggering anxiety or paranoia—especially common in inexperienced users or those consuming high-THC strains without CBD balance.
CBD’s Mechanism of Action
CBD (cannabidiol) is the second most abundant cannabinoid in cannabis and produces no psychoactive effects. Its mechanisms are more complex and indirect than THC’s. CBD has low affinity for CB1 and CB2 receptors and does not activate them in the standard agonist manner. Instead, it works through several other pathways.
FAAH inhibition: CBD partially inhibits fatty acid amide hydrolase, the enzyme that breaks down anandamide. By slowing anandamide degradation, CBD raises the brain’s natural endocannabinoid levels, producing anxiolytic and mood-stabilizing effects without direct CB1 activation.
5-HT1A receptor modulation: CBD acts as a partial agonist at serotonin 5-HT1A receptors, the same receptors targeted by SSRIs and buspirone. This is likely a key mechanism behind CBD’s anti-anxiety and antidepressant-adjacent effects.
TRPV1 activation: CBD activates transient receptor potential vanilloid 1 (TRPV1), a receptor involved in pain perception, inflammation, and body temperature regulation. This contributes to CBD’s anti-inflammatory and analgesic properties.
CB1 negative allosteric modulation: Research suggests CBD can also act as a negative allosteric modulator at CB1 receptors—changing the receptor shape so THC binds less effectively. This is one mechanism by which CBD attenuates THC’s anxiety-inducing effects, explaining why balanced THC:CBD strains tend to feel less anxious than pure high-THC varieties.
The Entourage Effect
The entourage effect—a term coined by Raphael Mechoulam and Shimon Ben-Shabat in 1998—describes the idea that the full spectrum of compounds in cannabis work synergistically to produce effects that isolated compounds cannot replicate. The most studied version of this involves cannabinoids and terpenes.
Terpenes are aromatic compounds responsible for the distinctive smells of different cannabis strains. They are not merely flavor molecules—they are pharmacologically active. Myrcene, the most common cannabis terpene, has sedating properties and may enhance THC’s penetration of the blood-brain barrier. Limonene has mood-elevating and anxiolytic properties. Linalool (also found in lavender) is calming. Pinene may counteract some of THC’s short-term memory impairment.
The clinical evidence for the entourage effect is still developing. Whole-plant cannabis extracts are frequently reported by users and clinicians to work differently from isolated THC or CBD, though large controlled trials directly comparing them remain limited.
Cannabinoid Comparison
| Cannabinoid | Primary Receptor | Psychoactive | Key Effects | Legal Status (US) |
|---|---|---|---|---|
| THC (delta-9) | CB1 agonist | Yes | Euphoria, analgesia, appetite, memory effects | Federally illegal; legal in 24+ states |
| CBD | FAAH inhibitor, 5-HT1A | No | Anxiolytic, anti-inflammatory, anti-seizure | Legal (hemp-derived; FDA-approved for epilepsy) |
| CBN | Weak CB1 agonist | Mildly | Sedation, possible sleep aid, antibacterial | Legal gray area |
| CBG | Weak CB1 + CB2 | No | Anti-inflammatory, antibacterial, IOP reduction | Generally legal (hemp-derived) |
| CBC | TRPV1, TRPA1 | No | Anti-inflammatory, antidepressant-like, analgesic | Generally legal (hemp-derived) |
Why Cannabis Affects People Differently
Two people can consume the same strain from the same batch and have completely different experiences. This variability is rooted in several well-documented biological and contextual factors.
Genetics and CB1 receptor density: Variants in the CNR1 gene (which encodes CB1) affect baseline receptor density and sensitivity. People with more or more sensitive CB1 receptors may experience stronger effects from the same dose. Variants in FAAH that affect anandamide levels also influence cannabis response.
Tolerance: Regular use triggers CB1 receptor downregulation. A 2–4 week tolerance break allows receptors to largely reset. Research suggests full receptor density restoration in daily users may take closer to four weeks of abstinence.
Body composition: THC is lipophilic and accumulates in fat tissue. People with higher body fat percentages may experience prolonged effects and detectable THC in their system for longer periods—with significant implications for drug testing.
Consumption method: Inhalation produces faster onset and more predictable dosing than edibles. Inexperienced users who underestimate edibles and redose early account for a large proportion of uncomfortable cannabis experiences.
Set and setting: Psychological and environmental context profoundly shapes the experience. Anxiety, unfamiliar environments, and negative expectations increase the likelihood of uncomfortable effects, regardless of dose or strain.
Frequently Asked Questions
How does cannabis get you high?
THC binds to CB1 receptors throughout the brain, mimicking anandamide. This triggers dopamine release in the reward pathway and alters activity in the prefrontal cortex, hippocampus, and limbic system, producing euphoria, relaxation, altered time perception, and heightened sensory awareness.
Why do edibles hit harder than smoking?
Liver metabolism converts THC into 11-OH-THC, a metabolite that crosses the blood-brain barrier more efficiently than THC itself. The result is stronger, longer-lasting effects at the same milligram dose. Delayed onset causes many users to redose before the first dose has peaked, compounding the effect.
Does tolerance reduce cannabis effects?
Yes. Regular use triggers CB1 receptor downregulation. A tolerance break of 2–4 weeks allows receptors to largely reset. Some research suggests full receptor density restoration takes closer to 4 weeks in daily users.
Can you build a tolerance to CBD?
CBD does not cause the same CB1 receptor downregulation as THC. Some users report reverse tolerance—needing less CBD over time as the ECS balances. Meaningful tolerance buildup to CBD has not been demonstrated in controlled research.